Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster
This study showed that the effectiveness of Shingrix in patients with inflammatory arthritis on immunomodulatory treatment was 50%, and the risk of venous thromboembolic events was increased in the 60-90 days after herpes zoster, supporting the recommendation that adults with inflammatory arthritis should receive vaccination against herpes zoster to reduce the risk of such events.
Authors
- Jeffrey R. Curtis (ORCID: https://orcid.org/0000-0002-8907-8976)
- Kevin L. Winthrop (ORCID: https://orcid.org/0000-0002-3892-6947)
- A. Gara
- Whitney S. Krueger (ORCID: https://orcid.org/0000-0003-1868-4300)
- Daniel H. Conrad (ORCID: https://orcid.org/0000-0002-4791-2694)
Institutions
- Oregon Health & Science University (US)
- AbbVie (United States) (US)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1186/s13075-025-03565-0
- Citations
- 11
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 14.90
Funders
- AbbVie